Table 3.
Ongoing RCTs
| Trial | Patients’ resectability | Phase | Regimen | Primary outcomes | Targeted population |
|---|---|---|---|---|---|
| JSAP-04 | R0/R1 | III | Adjuvant GEM + S1 vs. GEM | RFS | 300 |
| NEOPAC | R-PDAC | III | Neoadjuvant GEM + oxaliplatin vs. upfront surgery | PFS | 310 |
| NEOPA | R-PDAC | III | Neoadjuvant CRT with GEM vs. upfront surgery | 3-year OS | 410 |
| JASPAC04 | R-PDAC | II | Neoadjuvant CRT with S1 vs. neoadjuvant GEM + S1 | 2-year RFS | 100 |
| GABARNANCE | BR-PDAC | II/III | Neoadjuvant GEM + nab-paclitaxel vs. neoadjuvant CRT with S1 | R0 ratio/OS | 110 |
| JASPAC05 | BR-PDAC | II | Neoadjuvant CRT with S1 | R0 ratio | 50 |
| Prep-03, NS014-1 | BR-PDAC | I/II | Neoadjuvant CRT with GEM + S1 | MTD, RD/R0 ratio | 12–24 |
Currently ongoing trials of multimodality therapy for R/BR-PDAC